Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to day 8
Summary
This trial is testing a new drug called IA-14069 by giving a single dose to healthy men. The goal is to see how safe and tolerable the drug is, how it moves through the body, and if food changes its effects.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to day 8
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to day 8
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change from baseline in 12-lead ECG parameters
Incidence and severity of clinical laboratory abnormalities
Trial Design
5Treatment groups
Experimental Treatment
Group I: E mg IA-14069 or PlaceboExperimental Treatment2 Interventions
Group II: D mg IA-14069 or PlaceboExperimental Treatment2 Interventions
Group III: C mg IA-14069 or PlaceboExperimental Treatment2 Interventions
Period 1: Fasted condition → Period 2: Fed condition
Group IV: B mg IA-14069 or PlaceboExperimental Treatment2 Interventions
Group V: A mg IA-14069 or PlaceboExperimental Treatment2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
IA-14069
2021
Completed Phase 1
~40
Placebo
1995
Completed Phase 3
~2670
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
ILAb Co., Ltd.Lead Sponsor
1 Previous Clinical Trials
75 Total Patients Enrolled
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger